Back to News
Market Impact: 0.3
Pulnovo Medical anuncia los resultados del ensayo PADN-HF-PH en el Congreso ESC 2026
Source: PR Newswire
Healthcare & BiotechCompany FundamentalsTechnology & Innovation
Pulnovo Medical presentó en el Congreso ESC 2026 (y publicó simultáneamente en The New England Journal of Medicine) los resultados del ensayo PADN-HF-PH en 264 pacientes con PH-LHD, mostrando una reducción del 51% en el riesgo de empeoramiento clínico. El hito clínico respaldado por publicación en NEJM sugiere un avance significativo del producto/indicación evaluada, con potencial para mejorar la percepción del valor de la compañía.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- ‘How many canaries have we killed in the coal mine?’ — Wall Street debates if the latest AI bubble warnings are another head fake or the real thing
- Semiconductor market to remain solid ‘at least through next year,’ South Korea finance minister says
- Nasdaq Index: AI Selloff Deepens as Chips and CoreWeave Break
- Alphabet’s chief investment officer responds to Jefferies warning that the most likely outcome of the AI boom is massive U.S. capital destruction